Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 147, Issue 5, Pages 677-680Publisher
WILEY-BLACKWELL PUBLISHING, INC
DOI: 10.1111/j.1365-2141.2009.07892.x
Keywords
lymphoplasmacytic lymphoma; monoclonal IgM protein; rituximab; Waldenstrom macroglobulinaemia
Categories
Funding
- NCI NIH HHS [U10 CA049883, U10 CA013650, U10 CA066636, U10 CA023318, P30 CA082709, R01 CA111345, U10 CA021115] Funding Source: Medline
Ask authors/readers for more resources
P>Waldenstrom macroglobulinaemia is a low-grade, lymphoplasmacytic lymphoma that is responsive to rituximab. We report the role of a minor response in predicting overall outcomes. We extended follow-up of a previously described cohort (n = 69) treated with 4 weekly doses of rituximab and observed durable responses (median time to progression, 30 months; 5-year survival rate, 66%). Patients achieving a minor response [25-50% immunoglobulin M (IgM) reduction] appeared to do as well as those achieving an objective response (> 50% IgM reduction), which suggests that more aggressive or intensive therapy for minor responders is not required. Future studies of Waldenstrom macroglobulinaemia should report minor responses because they are associated with clinically meaningful benefits. This trial was registered at http://www.clinicaltrials.gov as #NCT00005609.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available